A Rare Disease CRO
Everyone Deserves to be Well
At Atlantic Research Group, we know how difficult it is to develop an orphan drug. But, we also know that great things happen when passionate people combine their strengths. Together, we create smart, feasible studies with protocols that reflect everyday life. We connect Individuals — even if there are only 50 in the entire world with a particular rare disease — to organizations that have the drive and know-how to develop potential treatments. We uncover far-reaching insights in orphan drug research, no matter how limited data may be. Let’s unite and finish the journey from trial to treatment.
The Journey to Droxidopa
Chelsea Therapeutics was in the process of licensing droxidopa for treating neurogenic orthostatic hypotension, but the study suffered from low patient recruitment. ARG was brought in to improve enrollment.
LEARN MORE ›
A Life-saving Drug's Race to America
Cinryze is used to treat hereditary angioedema, or HAE, a genetic defect that results in dysfunctional C1 esterase inhibitor. ARG helped Lev Pharmaceuticals conduct the trials and bring the drug to the market after a troubled history.
LEARN MORE ›
fuels passion and progress
The clinic isn’t the only place where we make strides. ARG works with a variety of rare disease organizations, advancing care alongside other dedicated individuals who advocate research.